17 10, 2023

Johnson & Johnson Beats Earnings & Raises Forecast – So Why is the Stock Falling?

By |2023-12-07T19:49:36+00:00October 17th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Yesterday, we highlighted Pfizer’s challenges in pivoting as a post-pandemic company. Today, its competitor Johnson & Johnson (JNJ) reported earnings itself.  But, Johnson & Johnson painted an entirely different picture - beating out the earnings estimate on the top and bottom line while raising the forecast for the remainder of the year. The company [...]

16 10, 2023

Why is Pfizer Up 5% After Cutting Sales Outlook? 3 Things Investors Need to See

By |2023-12-07T19:49:39+00:00October 16th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Pfizer (PFE) ended last week on a sour note, announcing after the market closed on Friday that it will cut $9 billion from its sales outlook. And yet, the stock is up more than 5% so far in Monday morning’s trading session. The full-year EPS has been adjusted to $1.45 to $1.65 on revenue [...]

13 09, 2023

Is Rocket Pharmaceuticals a Buy as the Stock Soars on FDA Trial Update? 3 Things to Consider

By |2023-12-07T19:52:55+00:00September 13th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Gene therapy developer Rocket Pharmaceuticals (RCKT) investors woke up in delight as shares skyrocketed in Wednesday morning’s pre-market trading session. When the bell sounded, the stock continued its trajectory and it currently sits 38% higher than it last closed at. This comes after the company announced that it has aligned with the Food and [...]

20 07, 2023

Johnson & Johnson Jumps 6% on Earnings Beat and Revised Guidance: Does it Deserve a Buy?

By |2023-12-07T20:46:04+00:00July 20th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Johnson & Johnson (JNJ) has had its ups and downs over the past few months, but it appears as if steady growth is ahead. The company has boosted its previous guidance for the year after Thursday’s earnings report came in well above analyst expectations. Johnson & Johnson saw sales growth of 6.3% for the [...]

18 07, 2023

AudioCodes is Down 55% This Year, and it May Get Worse: Time to Sell?

By |2023-12-07T20:46:09+00:00July 18th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , |

Recursion Pharmaceuticals (RXRX) just got an endorsement from one of Wall Street’s hottest stocks at the moment, and as such, has earned the attention of analysts, retail investors, and professionals alike. After securing a $50 million investment from Nvidia (NVDA), the RXRX shot up more than 76%. The two companies are more alike than [...]

30 06, 2023

Is it Time to Sell Walgreens Stock Amidst Dwindling Consumer Spending & COVID-Vax Demand?

By |2023-12-07T20:46:41+00:00June 30th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

Earlier this week, Walgreens (WBA) warned investors that profits would take a dive from previous estimates as a result of weakened consumer spending and dwindling demand for COVID-19 vaccinations. As a result, shares dropped more than 9% this week - now reaching their lowest levels in over a decade. CEO Rosalind Brewer noted that [...]

27 06, 2023

One Analyst Predicts Canopy Growth is Headed to Zero, Should You Cut Losses and Move On?

By |2023-12-07T20:46:54+00:00June 27th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

At one point, Canopy Growth (CGC) was valued at $19 billion. The stock traded at over $50/share at its peak. But today? It sits at a mere $0.49/share. And as dramatic a fall from grace as this story already is, one analyst expects the true end is near. Benchmark analyst Mike Hickey believes Canopy [...]

26 06, 2023

Eli Lilly is Up 38% in the Past 3 Months: What Keeps Pushing the Stock Higher, and Will it Continue?

By |2023-12-07T20:46:59+00:00June 26th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , |

While much of the recent focus within the stock market has been placed on the AI trend, one stock in the pharmaceutical industry has been on a surge so far this year: Eli Lilly (LLY). The stock sat at just $311/share at the start of March. And today, the stock sits at $452/share. But, [...]

15 05, 2023

Columbia Care is Up 20% After Earnings, But We Still See 3 Issues Investors Need to Be Aware Of

By |2023-12-07T20:50:59+00:00May 15th, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Columbia Care Inc. (CCHWF) started the week with a bang, releasing its 1st quarter earnings report and exceeding analyst expectations. As a result, the stock has climbed more than 20%. But as you’ll discover below, there are still 3 major issues investors should be aware of. The cannabis company posted revenue of $124.54 million, [...]

1 05, 2023

Will Protalix BioTherapeutics Keep Powering Higher After its 178% Run Up Since November 2022?

By |2023-12-07T20:56:34+00:00May 1st, 2023|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , |

Protalix BioTherapeutics, Inc. (PLX: NYSE AMEX and Tel Aviv Stock Exchange) is headquartered in Carmiel, Israel with an office in Hackensack, NJ, with a total of 197 employees. Protalix Ltd. was incorporated in 1993. It became a U.S public company on December 31, 2006. PLX is a biopharmaceutical company that develops, produces and commercializes [...]

Go to Top